MCID: BRS031
MIFTS: 28

Breast Rhabdomyosarcoma

Categories: Cancer diseases

Aliases & Classifications for Breast Rhabdomyosarcoma

MalaCards integrated aliases for Breast Rhabdomyosarcoma:

Name: Breast Rhabdomyosarcoma 12 14 69
Rhabdomyosarcoma of the Breast 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4060
NCIt 47 C5190
UMLS 69 C1332637

Summaries for Breast Rhabdomyosarcoma

MalaCards based summary : Breast Rhabdomyosarcoma, also known as rhabdomyosarcoma of the breast, is related to phagocyte bactericidal dysfunction and testis rhabdomyosarcoma. An important gene associated with Breast Rhabdomyosarcoma is MB (Myoglobin), and among its related pathways/superpathways are Immune response Function of MEF2 in T lymphocytes and Mesenchymal Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Cyclophosphamide and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and bone marrow, and related phenotypes are muscle and respiratory system

Related Diseases for Breast Rhabdomyosarcoma

Diseases related to Breast Rhabdomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 phagocyte bactericidal dysfunction 10.1 MB MYOG
2 testis rhabdomyosarcoma 9.9 MYOD1 MYOG
3 primary pulmonary lymphoma 9.8 MYOD1 MYOG
4 granular cell leiomyosarcoma 9.8 MYOD1 MYOG
5 colon leiomyosarcoma 9.8 MYOD1 MYOG
6 cutaneous liposarcoma 9.8 MYOD1 MYOG
7 spleen cancer 9.8 MB MYOD1
8 enamel hypoplasia cataract hydrocephaly 9.7 MYOD1 MYOG
9 rhabdomyosarcoma 9.7
10 transitional cell carcinoma 9.7 MB MYOD1
11 nodular tenosynovitis 9.7 MYOD1 MYOG
12 mucinous ovarian cystadenoma 9.7 MB MYOD1
13 pulmonary immaturity 9.7 MYOD1 MYOG
14 embryonal extrahepatic bile duct rhabdomyosarcoma 9.7 MB MYOD1
15 endodermal sinus tumor 9.7 MB MYOD1
16 glomerulonephritis 9.7 MB MYOD1
17 dextrocardia with situs inversus 9.7 MYOD1 MYOG
18 adenosarcoma 9.6 MB MYOG
19 cerebrum cancer 9.6 MB MYOD1
20 spindle cell sarcoma 9.5 MB MYOD1
21 hyperbiliverdinemia 9.5 MYOD1 MYOG
22 46xy sex reversal 5 9.5 MB MYOD1
23 eosinophilic variant of chromophobe renal cell carcinoma 9.4 MB MYOD1
24 bile duct sarcoma 9.3 MB MYOD1 MYOG
25 lateral medullary syndrome 9.3 MB MYOD1 MYOG
26 melanotic medulloblastoma 9.3 MB MYOD1 MYOG
27 ischemia 9.3 MB MYOD1 MYOG
28 lung clear cell-sugar-tumor 9.3 MB MYOD1 MYOG
29 mediastinum rhabdomyosarcoma 9.3 MB MYOD1 MYOG
30 prostate embryonal rhabdomyosarcoma 9.3 MB MYOD1 MYOG
31 central nervous system rhabdomyosarcoma 9.3 MB MYOD1 MYOG
32 rhabdomyosarcoma 2, alveolar 9.2 MB MYOD1 MYOG
33 prostate rhabdomyosarcoma 9.2 MB MYOD1 MYOG
34 adult intracranial malignant hemangiopericytoma 9.1 MB MYOD1

Graphical network of the top 20 diseases related to Breast Rhabdomyosarcoma:



Diseases related to Breast Rhabdomyosarcoma

Symptoms & Phenotypes for Breast Rhabdomyosarcoma

MGI Mouse Phenotypes related to Breast Rhabdomyosarcoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.13 MB MYOD1 MYOG
2 respiratory system MP:0005388 8.8 MB MYOD1 MYOG

Drugs & Therapeutics for Breast Rhabdomyosarcoma

Drugs for Breast Rhabdomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
2
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
3
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
4
Palivizumab Approved, Investigational Phase 3 188039-54-5
5
Ribavirin Approved Phase 3 36791-04-5 37542
6
Fluconazole Approved Phase 3 86386-73-4 3365
7
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
8
Captopril Approved Phase 3 62571-86-2 44093
9
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
10
Mycophenolic acid Approved Phase 3 24280-93-1 446541
11 Alkylating Agents Phase 3
12 Antirheumatic Agents Phase 3,Phase 2
13 Immunosuppressive Agents Phase 3,Phase 2
14 Anti-Bacterial Agents Phase 3
15 Antifungal Agents Phase 3
16 Anti-Infective Agents Phase 3,Phase 2
17 Antiparasitic Agents Phase 3
18 Antiprotozoal Agents Phase 3
19 Liposomal amphotericin B Phase 3
20 Antibodies Phase 3
21 Antibodies, Monoclonal Phase 3
22 Antimetabolites Phase 3,Phase 2
23 Antiviral Agents Phase 3,Phase 2
24 Immunoglobulins Phase 3
25 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
26 Cytochrome P-450 CYP3A Inhibitors Phase 3
27 Cytochrome P-450 Enzyme Inhibitors Phase 3
28 Hormone Antagonists Phase 3
29 Hormones Phase 3
30 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
31 Hydroxyitraconazole Phase 3
32 Steroid Synthesis Inhibitors Phase 3
33 Acyclovir Phase 3
34 valacyclovir Phase 3
35 Angiotensin-Converting Enzyme Inhibitors Phase 3
36 Antihypertensive Agents Phase 3,Phase 1
37 HIV Protease Inhibitors Phase 3
38
protease inhibitors Phase 3
39 Antibiotics, Antitubercular Phase 3
40
Lenograstim Approved Phase 2 135968-09-1
41
Oprelvekin Approved, Investigational Phase 2 145941-26-0
42
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
43
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
44
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
45
rituximab Approved Phase 2 174722-31-7 10201696
46 Adjuvants, Immunologic Phase 2
47 Anti-HIV Agents Phase 2
48 Anti-Retroviral Agents Phase 2
49 Interferon-alpha Phase 2
50 interferons Phase 2

Interventional clinical trials:

(show all 29)

id Name Status NCT ID Phase Drugs
1 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
2 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
3 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
4 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
5 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
6 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
7 Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors Completed NCT00004157 Phase 2
8 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2
9 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
10 Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer Completed NCT00003408 Phase 2
11 Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00002673 Phase 2
12 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
13 PEN-866 in Patients With Advanced Solid Malignancies Recruiting NCT03221400 Phase 1, Phase 2 PEN-866
14 Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant Terminated NCT00617929 Phase 2 clofarabine
15 Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant Withdrawn NCT00728585 Phase 2
16 Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections Unknown status NCT00769613 Phase 1
17 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
18 Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy Completed NCT00509691 Phase 1
19 Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant Completed NCT00569283 Phase 1
20 Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors Not yet recruiting NCT02897986 Phase 1 administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination
21 Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00957736 Phase 1
22 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Unknown status NCT00499733 cyclophosphamide
23 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant Completed NCT00408681 lithium carbonate
24 Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00079222 itraconazole;voriconazole
25 Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation Completed NCT00003538
26 Familial Investigations of Childhood Cancer Predisposition Recruiting NCT03050268
27 Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer Active, not recruiting NCT00949052
28 Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection Withdrawn NCT00378781 Heparin;Minocycline-EDTA
29 Early Detection of Graft-Versus-Host Disease in Patients Undergoing a Donor Bone Marrow Transplant Withdrawn NCT00898612

Search NIH Clinical Center for Breast Rhabdomyosarcoma

Genetic Tests for Breast Rhabdomyosarcoma

Anatomical Context for Breast Rhabdomyosarcoma

MalaCards organs/tissues related to Breast Rhabdomyosarcoma:

39
Breast, Bone, Bone Marrow, Liver

Publications for Breast Rhabdomyosarcoma

Articles related to Breast Rhabdomyosarcoma:

id Title Authors Year
1
Fatal breast rhabdomyosarcoma in a 15 year old primigravida. ( 2379516 )
1990
2
Cytology of fine needle aspiration biopsy of primary breast rhabdomyosarcoma in an adolescent girl. ( 3859144 )
1985

Variations for Breast Rhabdomyosarcoma

Expression for Breast Rhabdomyosarcoma

Search GEO for disease gene expression data for Breast Rhabdomyosarcoma.

Pathways for Breast Rhabdomyosarcoma

Pathways related to Breast Rhabdomyosarcoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
11.1 MYOD1 MYOG
2 10.61 MYOD1 MYOG

GO Terms for Breast Rhabdomyosarcoma

Cellular components related to Breast Rhabdomyosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor complex GO:0005667 8.62 MYOD1 MYOG

Biological processes related to Breast Rhabdomyosarcoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 muscle organ development GO:0007517 9.51 MYOD1 MYOG
2 skeletal muscle tissue development GO:0007519 9.49 MYOD1 MYOG
3 skeletal muscle cell differentiation GO:0035914 9.48 MYOD1 MYOG
4 cellular response to estradiol stimulus GO:0071392 9.46 MYOD1 MYOG
5 skeletal muscle fiber development GO:0048741 9.43 MYOD1 MYOG
6 positive regulation of muscle cell differentiation GO:0051149 9.4 MYOD1 MYOG
7 myoblast differentiation GO:0045445 9.37 MYOD1 MYOG
8 positive regulation of myoblast differentiation GO:0045663 9.32 MYOD1 MYOG
9 positive regulation of myoblast fusion GO:1901741 9.26 MYOD1 MYOG
10 myotube differentiation GO:0014902 9.16 MYOD1 MYOG
11 positive regulation of skeletal muscle fiber development GO:0048743 8.96 MYOD1 MYOG
12 muscle cell fate commitment GO:0042693 8.62 MYOD1 MYOG

Molecular functions related to Breast Rhabdomyosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.4 MYOD1 MYOG
2 protein dimerization activity GO:0046983 9.37 MYOD1 MYOG
3 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0001228 9.32 MYOD1 MYOG
4 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.26 MYOD1 MYOG
5 core promoter binding GO:0001047 9.16 MYOD1 MYOG
6 chromatin DNA binding GO:0031490 8.96 MYOD1 MYOG
7 E-box binding GO:0070888 8.62 MYOD1 MYOG

Sources for Breast Rhabdomyosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....